The mechanisms behind the protective effects of SGLT2 inhibitors on cardiovascular disease are not fully understood but may involve reductions in glucose, systolic blood pressure, and arteriosclerosis, as well as protective effects on the heart and kidneys [9, 10, 18–20]. The gene discussed is SLC5A2; the disease is arteriosclerosis.